Dr. Yongxin Zhang, CEO of Zyxell Inc., graduated from Beijing Medical University for both of his MD (1983) and PhD (1989), and received postdoctoral training in Baylor College of Medicine (1996-2004). He has the expertise in the research of immunology, especially in cancer cell therapy. His research work on aging immunology revealed the mechnisim of the compromised immune responses in aged subjects and exhibited the preventive effects of ex vivo reactivated and expanded lymphocytes on influenza virus infection in aged animals. He is also the inventor of ZYX Bioreactor, which has a great advantages in expansion of immunocytes and hepatopoiethic stem cells over other systems. He has more than 30 publications in peer-reviewed journals.